PARP1 and triple-negative breast carcinoma: Similarly, the use of an oral PARP inhibitor, olaparib, often after chemotherapy had failed, resulted in tumor regression in up to 41% of patients carrying BRCA mutations, most of whom had triple-negative breast cancer [28].